Latest News and Press Releases

In the ongoing GEMSTONE-301 Phase 3 study, sugemalimab, administered after treatment with either concurrent or sequential chemoradiotherapy, demonstrated a statistically significant improvement in...

CAMBRIDGE, Mass., July 28, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at...

Marketing authorization application is EQRx’s first submission to a regulatory agencyApplication is based on data from pivotal Phase 3 AENEAS trial in the first-line treatment of EGFR-mutated...

CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at...

In a Phase 3 clinical trial, the addition of sugemalimab to chemotherapy improved median overall survival by 8.5 months versus placebo plus chemotherapy in people with previously untreated Stage IV...

New data on lead oncology programs aumolertinib and sugemalimab to be presented at the 2022 ASCO Annual Meeting, including pre-specified interim overall survival (OS) data from the Phase 3...

CAMBRIDGE, Mass., April 29, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at...

First presentation of data from a pre-specified interim overall survival analysis of the Phase 3 GEMSTONE-302 study of sugemalimab in patients with previously untreated Stage IV non-small cell lung...

First regulatory submissions for lead oncology programs aumolertinib and sugemalimab are expected to be ex-U.S. in 2H 2022; continuing to engage in discussions with the FDAContinue expanding the...

CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at...